The Two-Drug HIV Pill That Wasn't Supposed to Make It
Merck's islatravir nearly died after alarming safety signals forced the FDA to halt clinical trials. Now it's the backbone of Idvynso, the first two-drug HIV regimen that ditches the most popular drug class in the field. The comeback story is worth reading.
For years, the playbook for treating HIV looked the same: three drugs, one pill, take it every day. The cocktail approach worked brilliantly, turning a death sentence into a manageable chronic condition. But three drugs also means three chances for side effects, three sets of drug interactions, and a nagging question that researchers couldn't shake: do we actually need all three?
On April 20, the FDA answered that question with a resounding "not always." Idvynso, a once-daily pill combining just two drugs (doravirine and islatravir), is now approved for adults whose HIV is already under control. It's the kind of simplification that sounds minor on paper but could reshape how millions of people manage their treatment.
And the road to get here? It nearly collapsed entirely.
A Comeback Story Nobody Expected
Merck's journey with islatravir has been anything but smooth. The drug belongs to a brand-new class called NRTTIs (nucleoside reverse transcriptase translocation inhibitors), which is a mouthful that basically means it blocks HIV's copying machinery in a way no other drug on the market does. Think of it like jamming a photocopier, except instead of crumpling paper, islatravir wedges itself into the virus's genetic material and stops it from replicating through three different mechanisms simultaneously.
Sounds great, right? It was, until the FDA put clinical holds on islatravir studies after noticing something alarming: patients' CD4+ T-cell counts were dropping. Those are the very immune cells that HIV destroys, so watching them decline in a drug meant to help HIV patients was, to put it mildly, not ideal. It was like hiring a bodyguard who occasionally punches your friends.
Merck's solution was elegant. They slashed the dose. The approved version of Idvynso contains just 0.25 mg of islatravir, a fraction of what earlier trials tested. At this lower dose, the CD4 concerns faded into the background while the antiviral potency stayed intact. The FDA accepted Merck's new drug application in July 2025, and approval came ahead of the April 28 target date.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Idvynso's approval rests on two Phase 3 studies involving over 1,000 participants, all of whom already had their virus under control on existing medications. The question wasn't whether these patients could be suppressed; they already were. The question was whether they could stay suppressed on fewer drugs.
The answer: yes, convincingly.
In Trial 051, an open-label study with 553 participants switching from their current regimen, only 1% of people on Idvynso had detectable virus at 48 weeks. The control group? Also 1%. Dead even.
Trial 052 was even more interesting. This double-blind study pitted Idvynso against Biktarvy, Gilead's blockbuster three-drug combo that dominates the HIV market like LeBron dominates highlight reels. Among 513 participants who switched, just 1% on Idvynso had detectable virus compared to 1% on continued Biktarvy. The two-drug regimen matched the three-drug gold standard.
The longer-term data at 96 weeks told a similar story. Viral suppression rates held steady at roughly 89% for Idvynso versus 90% for the comparator. Non-inferiority confirmed, check in the box.
No new serious drug-related adverse events emerged.
If your eyes glazed over at "non-INSTI," stay with me. This is actually the most important part.
Nearly every modern HIV regimen relies on a class of drugs called integrase strand-transfer inhibitors (INSTIs). Biktarvy uses one. Cabenuva, the injectable option, uses one. Dolutegravir, the WHO's recommended backbone, is one. INSTIs are everywhere because they work incredibly well.
But when one drug class dominates an entire disease, you've got a single-point-of-failure problem. If a patient develops resistance to INSTIs, or can't tolerate them, or has drug interactions that rule them out, the options shrink fast. It's like a basketball team that only knows how to run one play; fine until someone figures out how to defend it.
Idvynso is the first two-drug regimen that completely sidesteps INSTIs. Doravirine is an NNRTI (non-nucleoside reverse transcriptase inhibitor), and islatravir is the first-in-class NRTTI. Neither touches the integrase pathway. For patients who need an INSTI-free option, this isn't just another choice on the menu. It's the only simplified choice on the menu.
It's also tenofovir-free, which matters for patients with kidney concerns since tenofovir can be tough on the kidneys over decades of use.
The Fine Print (Because There's Always Fine Print)
Idvynso isn't for everyone, and the label makes that clear. It's approved specifically for adults who are already virologically suppressed (viral load below 50 copies per milliliter) on a stable regimen for at least three months. No history of treatment failure. No known resistance to doravirine.
There are a few notable restrictions. Strong CYP3A inducers (certain drugs that rev up your liver's metabolism) are off-limits.
Perhaps most importantly, Idvynso does not cover hepatitis B. Many HIV medications pull double duty by also suppressing hepatitis B, which frequently co-occurs with HIV. Patients with both infections will need separate hepatitis B management, adding complexity rather than reducing it.
Expect Idvynso to hit U.S. pharmacies after May 11, 2026.
The Bigger Picture: HIV Treatment Is Getting a Makeover
Idvynso drops into an HIV treatment landscape that's evolving faster than it has in years. The theme of 2026 is options, options, options.
On the injectable front, Cabenuva (cabotegravir/rilpivirine) continues expanding, with new data supporting every-two-month injections in adolescents. For people who struggle with daily pills, that's transformative. Even further out, experimental agents like VH-499 and GS-3242 are showing pharmacokinetic profiles that could support twice-yearly dosing. Imagine managing HIV with two shots a year.
Biktarvy remains the 800-pound gorilla in daily oral treatment. But Gilead isn't standing still: a new bictegravir/lenacapavir single tablet has shown strong viral suppression rates in switch patients.
And then there's Merck's own pipeline beyond Idvynso. The company is testing islatravir combined with a different partner drug (ulonivirine) as a potential once-weekly oral HIV treatment, currently in Phase 2b. If that works, we're talking about going from 365 pills a year to 52.
So What Does This Mean for Patients?
The practical impact of Idvynso comes down to three words: fewer moving parts. For the roughly 1.2 million Americans living with HIV, most of whom take daily medication, switching from three active drugs to two (while maintaining the same level of viral control) means less potential for long-term toxicity and fewer drug interactions to worry about.
It also represents something more symbolic. For decades, HIV treatment was defined by its complexity: handfuls of pills, strict timing, brutal side effects. Each simplification, from multi-pill regimens to single-tablet combos to two-drug options, chips away at the burden of living with the virus.
Idvynso isn't a cure. It's not even the most dramatic advance in HIV this year (those injectable options are genuinely stunning). But it's proof that a drug class everyone once worried was dead on arrival can be resurrected with smart dose engineering and careful clinical work.
Merck's persistence paid off. And for patients who need an INSTI-free path forward, that persistence might just change their lives.
Science & Discovery5 min read
Flagship's New Bet: A DNA That Acts Like mRNA's Cooler, Longer-Lasting Cousin
Flagship Pioneering just launched Serif Biomedicines with $50M to develop "modified DNA" therapeutics, a new modality designed to combine mRNA's flexibility with gene therapy's staying power. It's an ambitious bet on solving genetic medicine's biggest trade-off.
